$SLNO soars on $2.9 billion Neurocrine Biosciences buyout. 📈
The deal will see Neurocrine Biosciences expand its endocrinology and rare disease portfolio. https://t.co/U7HZOux1FM
@YahooFinance
Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,’ analysts say